11.JPG)
Biopsy Devices Market Size is valued at USD 6.84 Bn in 2023 and is predicted to reach USD 20.04 Bn by the year 2031 at a 14.51% CAGR during the forecast period for 2024-2031.
A biopsy is a surgical procedure that takes tissue from an organ to detect the presence or extent of disease, most commonly malignant and inflammatory conditions. The most common people who carry it out are radiologists, surgeons, and interventional cardiologists. Biopsies are used to perform on any organ using specific biopsy instruments as a confirming test for cancer and celiac disease. The application of each biopsy equipment differs depending on the type of organ under consideration. The rising global cancer prevalence, untapped potential in emerging nations, particularly in Asia Pacific, and the improvement of healthcare infrastructure in these regions are among the important themes driving market growth.
However, the COVID-19 pandemic had a moderate impact on the market. Prioritizing cancer patients was difficult because healthcare personnel were mostly focused on COVID-19 patients. With a greater emphasis on avoiding viral infection, most people preferred fewer trips to healthcare settings. To some extent, this had a negative impact on the biopsy market. However, once the globe returned to normalcy and cancer cases increased, the market swiftly rebounded.
Competitive Landscape
Some Major Key Players In The Biopsy Devices Market:
- Argon Medical Devices, Inc.
- Braun SE
- Becton
- Dickinson and Company
- Boston Scientific Corporation
- Cardinal Health, Inc.
- Cook Group Incorporated
- Conmed Corporation
- FUJIFILM Holdings Corporation
- GE Healthcare
- Inrad, Inc.
- Medtronic plc
- Olympus Corporation
- Siemens Healthineers AG
- Stryker Corporation
- Zamar Care
- Changzhou Jiuhong Medical Instrument Co., Ltd.
- Kindly (KDL) Meditech
- Ningbo Xinwell Medical Technology Co., LTD.
- Shenzhen Manners Technology Co., Ltd.
- Zhejiang Soudon Medical Technology Co., Ltd
- Agilent Technologies, Inc.
- BGI Group
- Biocept, Inc.
- Bio-Rad Laboratories, Inc.
- Dxcover Limited
- Elypta Limited
- Hoffmann-La Roche Ltd
- Illumina, Inc.
- Micronoma
- QIAGEN
- Revvity, Inc.
- Sysmex Corporation
- Thermo Fisher Scientific Inc
- Others
Market Segmentation:
The Biopsy Devices Market is segmented based on Product Type, Biopsy Type, Disease Type, Anatomy, and Guidance Technique. By Product Type segment comprises Needle Biopsy Devices (Guidance Systems, Biopsy Consoles, Site Markers, Biopsy Guns (Automated Systems, Semi-Automated Systems), Needles), Skin Biopsy Devices (Punch Biopsy Instruments, Shave Biopsy Instruments), and Consumables (Forceps, Trocars, Trays, Other Consumables). Whereas the Biopsy Type segment consists of Tissue Biopsy, which is again divided into Needle Biopsy, Surgical Biopsy and Skin Biopsy, and Liquid Biopsy. The Anatomy segment includes Breast, Lung, Bone, Liver, Uterus/Cervix/Ovary, Abdomen, Prostate, Cardiac, Skin, and Others. By Disease Type, the market is segmented into Cancer, Infections, Autoimmune Disorders, Non-Cancerous Indications, and Others. According to the Guidance Technique segment, the market is divided into Growth-Share Analysis, Ultrasound-Guided Biopsy, X-Ray-Guided Biopsy, MRI-Guided Biopsy, and CT-Guided Biopsy.
Based On The Product Type, The Needle Biopsy Devices Segment Is Accounted As A Major Contributor In The Biopsy Devices Market.
The needle biopsy devices sector held the most significant portion of the market. Needle biopsies are characterized by their minimally invasive nature, allowing for prompt execution while minimizing patient distress. As a result, they are favored by healthcare providers and patients alike. Furthermore, the escalating prevalence of cancer and the imperative for timely detection have heightened the need for tissue sampling, specifically for lesions that are conventionally challenging to access.
The Breast Anatomy Segment Witnessed Growth At A Rapid Rate.
The Breast anatomy segment is projected to grow rapidly in the global Biopsy Devices Market. The current domination of this category is mostly because of the availability of many cancer therapies monitoring liquid biopsies that key players now offer.
In The Region, The North American Biopsy Devices Market Holds A Significant Revenue Share.
The North America Biopsy Devices Market is expected to record the maximum market share in revenue in the near future. Owing to the existence of established market players in the region, it is expected to continue to account for a sizable part of the market throughout the projection period. The regional market will likely benefit from high market penetration rates of technologically advanced equipment such as vacuum-assisted biopsy systems and rapidly expanding demand for disposable devices. Asia Pacific offers numerous prospects for market expansion. The rapid improvement of healthcare infrastructure in growing Asia Pacific countries, the prevalence of significant unmet patient demands, and the rising incidence of cancer are expected to drive regional market expansion.
Recent Developments:
- In Sept 2023, A revolutionary collaboration has been declared between Roche France, Foundation Medicine, and the Institute Gustave Roussy to provide cancer patients in France with in-house liquid biopsy genomic testing. By transferring FoundationOne®Liquid CDx technology to the Institute Gustave Roussy, Roche France and Foundation Medicine have the potential to provide liquid biopsy testing for comprehensive genomic profiling (CGP) in all patients in France diagnosed with advanced cancer.
- In August 2022, Mammotome announced the release of the Mammotome DualCoreTM biopsy system, the company's first twin-stage core biopsy tool. This novel core biopsy device adds to the Mammotome ultrasound-guided breast biopsy portfolio, which already includes the Mammotome® Elite Tetherless Vacuum-Assisted Biopsy Device (tetherless VABB) and the Mammotome RevolveTM Dual Vacuum-Assisted Breast Biopsy System (tethered VABB).
Biopsy Devices Market Report Scope
|
Report Attribute |
Specifications |
|
Market Size Value In 2023 |
USD 6.84 Bn |
|
Revenue Forecast In 2031 |
USD 20.04 Bn |
|
Growth Rate CAGR |
CAGR of 14.51% from 2024 to 2031 |
|
Quantitative Units |
Representation of revenue in US$ Million and CAGR from 2024 to 2031 |
|
Historic Year |
2019 to 2023 |
|
Forecast Year |
2024-2031 |
|
Report Coverage |
The forecast of revenue, the position of the company, the competitive market structure, growth prospects, and trends |
|
Segments Covered |
By Product Type, By Biopsy Type, By Anatomy, By Disease Type, By Guidance Technique |
|
Regional Scope |
North America; Europe; Asia Pacific; Latin America; Middle East & Africa |
|
Country Scope |
U.S.; Canada; U.K.; Germany; China; India; Japan; Brazil; Mexico ;The UK; France; Italy; Spain; China; Japan; India; South Korea; South East Asia; South Korea; South East Asia |
|
Competitive Landscape |
Argon Medical Devices, Inc., B. Braun SE, Becton, Dickinson and Company, Boston Scientific Corporation, Cardinal Health, Inc., Cook Group Incorporated, Conmed Corporation, FUJIFILM Holdings Corporation, GE Healthcare, Inrad, Inc., Medtronic plc, Olympus Corporation, Siemens Healthineers AG, Stryker Corporation, Zamar Care, Changzhou Jiuhong Medical Instrument Co., Ltd., Kindly (KDL) Meditech, Ningbo Xinwell Medical Technology Co., LTD., Shenzhen Manners Technology Co., Ltd., Zhejiang Soudon Medical Technology Co., Ltd, Agilent Technologies, Inc., BGI Group, Biocept, Inc., Bio-Rad Laboratories, Inc., Dxcover Limited, Elypta Limited, F. Hoffmann-La Roche Ltd, Illumina, Inc., Micronoma, QIAGEN, Revvity, Inc., Sysmex Corporation, and Thermo Fisher Scientific Inc. |
|
Customization Scope |
Free customization report with the procurement of the report and modifications to the regional and segment scope. Particular Geographic competitive landscape. |
|
Pricing And Available Payment Methods |
Explore pricing alternatives that are customized to your particular study requirements. |
Corporate
Office :
Office No.5170, 5th Floor Marvel Fuego, Magarpatta Rd, Pune, 411028
info@insightaceanalytic.com
